share_log

Further Weakness as Dezhan Healthcare (SZSE:000813) Drops 6.1% This Week, Taking Five-year Losses to 63%

Further Weakness as Dezhan Healthcare (SZSE:000813) Drops 6.1% This Week, Taking Five-year Losses to 63%

德展医疗(深交所股票代码:000813)本周下跌6.1%,使五年亏损降至63%,进一步疲软
Simply Wall St ·  2023/12/20 17:22

We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly. Zooming in on an example, the Dezhan Healthcare Company Limited (SZSE:000813) share price dropped 65% in the last half decade. That is extremely sub-optimal, to say the least. And we doubt long term believers are the only worried holders, since the stock price has declined 22% over the last twelve months. Unfortunately the share price momentum is still quite negative, with prices down 9.5% in thirty days. However, we note the price may have been impacted by the broader market, which is down 5.2% in the same time period.

我们认为明智的长期投资是必经之路。但在此过程中,一些股票将表现不佳。举个例子,德展医疗有限公司(深圳证券交易所代码:000813)的股价在过去五年中下跌了65%。至少可以说,这非常不理想。我们怀疑长期信徒是唯一担心的持有者,因为股价在过去十二个月中下跌了22%。不幸的是,股价势头仍然相当不利,股价在三十天内下跌了9.5%。但是,我们注意到价格可能受到大盘的影响,同期下跌了5.2%。

If the past week is anything to go by, investor sentiment for Dezhan Healthcare isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果说过去一周有意义的话,投资者对德展医疗的情绪并不乐观,所以让我们看看基本面与股价之间是否存在不匹配的情况。

Check out our latest analysis for Dezhan Healthcare

查看我们对德展医疗的最新分析

Dezhan Healthcare isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Dezhan Healthcare目前没有盈利,因此大多数分析师会着眼于收入的增长,以了解基础业务的增长速度。当一家公司没有盈利时,我们通常预计收入会有良好的增长。可以想象,收入的快速增长如果持续下去,通常会带来利润的快速增长。

In the last five years Dezhan Healthcare saw its revenue shrink by 43% per year. That puts it in an unattractive cohort, to put it mildly. Arguably, the market has responded appropriately to this business performance by sending the share price down 10% (annualized) in the same time period. We don't generally like to own companies that lose money and don't grow revenues. You might be better off spending your money on a leisure activity. This looks like a really risky stock to buy, at a glance.

在过去的五年中,德展医疗的收入每年减少43%。客气地说,这使它成为一个没有吸引力的群体。可以说,市场对这一业务表现做出了适当的反应,使股价在同一时期下跌了10%(按年计算)。我们通常不喜欢拥有亏损且收入不增长的公司。你最好把钱花在休闲活动上。一目了然,这看起来像是一只非常有风险的股票。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下图显示了收入和收入在一段时间内的跟踪情况(如果你点击图片,你可以看到更多的细节)。

earnings-and-revenue-growth
SZSE:000813 Earnings and Revenue Growth December 20th 2023
SZSE: 000813 2023年12月20日收益和收入增长

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

资产负债表的强度至关重要。可能值得一看我们关于其财务状况如何随着时间的推移而变化的免费报告。

A Different Perspective

不同的视角

While the broader market lost about 7.3% in the twelve months, Dezhan Healthcare shareholders did even worse, losing 22%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Dezhan Healthcare you should be aware of, and 1 of them is a bit unpleasant.

尽管整个市场在十二个月中下跌了约7.3%,但德展医疗股东的表现甚至更糟,下跌了22%。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年中10%的年化亏损还要糟糕。总的来说,长期股价疲软可能是一个坏兆头,尽管逆势投资者可能希望研究该股以期出现转机。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。一个很好的例子:我们发现了你应该注意的德展医疗的两个警告信号,其中一个有点不愉快。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发